Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P01229
UPID:
LSHB_HUMAN
Alternative names:
Luteinizing hormone subunit beta
Alternative UPACC:
P01229; Q9UDI0
Background:
Lutropin subunit beta, also known as Luteinizing hormone subunit beta, plays a pivotal role in human reproduction. It is essential for promoting spermatogenesis in males and ovulation in females by stimulating the synthesis of steroids in the testes and ovaries. This protein's functionality underscores its importance in the delicate balance of the reproductive system.
Therapeutic significance:
The protein is directly linked to Hypogonadotropic hypogonadism 23, a condition marked by absent or incomplete sexual maturation and low levels of circulating gonadotropins and testosterone. Understanding the role of Lutropin subunit beta could open doors to potential therapeutic strategies for treating this form of hypogonadism, enhancing fertility and sexual health.